Biosciences reports year-end results with narrowing losses.

2004 DEC 2 - (NewsRx.com & NewsRx.net) -- PURE Bioscience (OTCBB:PURE) reported revenues from continuing bioscience segment operations of approximately $263,500 for the fiscal year ended July 31, 2004, compared to revenues of $115,700 in the prior year.

The company announced a narrowing loss from continuing operations of ($2,823,600), or ($0.21) per share, compared to a loss of ($3,663,900), or ($0.40) per share, in the prior year.

Although the company continues to operate the water treatment division pending its sale, financial results related to the water treatment division are presented as discontinued operations. Revenues from the discontinued water treatment operation for the fiscal year ended July 31, 2004, were approximately $1,800,600, with operating income of $515,900, or $0.04 per share.

Revenues from discontinued operations for fiscal year 2003 were $2,473,800, with operating income of approximately $379,900, or $0.04 per share. At July 31, 2004, the company had a backlog of $458,000 of water treatment products.

PURE Bioscience's flagship technology is a patented, aqueous antimicrobial called silver dihydrogen citrate (SDC). SDC is an electrolytically generated source of stabilized ionic silver that can serve as the basis for a broad range of products in diverse markets.

Colorless, odorless, tasteless and non caustic, SDC formulates well with other compounds. PURE produces and markets preformulated, ready-to-use product, as well as varying strengths of silver dihydrogen citrate concentrate as an additive or raw material for inclusion in other companies' products.

PURE currently has U.S. Environmental Protection Agency (EPA) registration for its 2400-parts-per-million (ppm) technical grade SDC concentrate (trade name Axenohl) as well as for its Axen and Axen30 hard surface disinfectant products for commercial, industrial and consumer applications, including restaurants, homes and medical facilities.